ChromaVision develops test for aggressive cancers
This article was originally published in Clinica
Executive Summary
ChromaVision Medical Systems is developing a test for assessing the aggressiveness of cancer based on its Automated Cellular Imaging System. In a collaboration with the University of Southern California, Kenneth Norris Jr Comprehensive Cancer Center, the company plans to develop an objective tumour angiogenesis test that evaluates the density of new blood vessels, which enable tumour growth. The new test could help identify patients who have particularly aggressive cancers and who may benefit from new anti-angiogenesis drugs currently under development, said the San Juan Capistrano, California-based company.